Baseline patient characteristics
Characteristic . | All patients, N = 31, median (range) or n (%) . | Avelumab treatment group, median (range) or n (%) . | ||||
---|---|---|---|---|---|---|
70 mg Q2W, n = 6 . | 350 mg Q2W, n = 7 . | 500 mg Q2W, n = 6 . | 500 mg Q3W, n = 6 . | 10 mg/kg Q2W, n = 6 . | ||
Age, y | 38.0 (22.0-81.0) | 57.0 (31.0-78.0) | 48.0 (30.0-71.0) | 36.5 (22.0-56.0) | 35.0 (25.0-78.0) | 31.5 (25.0-81.0) |
Age group, y | ||||||
<65 | 24 (77.4) | 5 (83.3) | 4 (57.1) | 6 (100.0) | 4 (66.7) | 5 (83.3) |
≥65 | 7 (22.6) | 1 (16.7) | 3 (42.9) | 0 | 2 (33.3) | 1 (16.7) |
ECOG performance status | ||||||
0 | 14 (45.2) | 2 (33.3) | 4 (57.1) | 3 (50.0) | 3 (50.0) | 2 (33.3) |
1 | 17 (54.8) | 4 (66.7) | 3 (42.9) | 3 (50.0) | 3 (50.0) | 4 (66.7) |
Sex | ||||||
Male | 24 (77.4) | 3 (50.0) | 6 (85.7) | 5 (83.3) | 5 (83.3) | 5 (83.3) |
Female | 7 (22.6) | 3 (50.0) | 1 (14.3) | 1 (16.7) | 1 (16.7) | 1 (16.7) |
Geographic region | ||||||
North America | 10 (32.2) | 2 (33.3) | 2 (28.6) | 2 (33.3) | 2 (33.3) | 2 (33.3) |
Western Europe | 21 (67.7) | 4 (66.7) | 5 (71.4) | 4 (66.7) | 4 (66.7) | 4 (66.7) |
No. of prior anticancer therapy regimens | ||||||
1 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 2 (6.5) | 0 | 0 | 0 | 1 (16.7) | 1 (16.7) |
3 | 9 (29.0) | 2 (33.0) | 2 (28.6) | 1 (16.7) | 2 (33.3) | 2 (33.3) |
≥4 | 20 (64.5) | 4 (66.7) | 5 (71.4) | 5 (83.3) | 3 (50.0) | 3 (50.0) |
Prior treatment with brentuximab vedotin | 31 (100.0) | 6 (100.0) | 7 (100.0) | 6 (100.0) | 6 (100.0) | 6 (100.0) |
Patients with prior HSCT | 13 (41.9) | 2 (33.3) | 2 (28.6) | 4 (66.7) | 4 (66.7) | 1 (16.7) |
Type of HSCT | ||||||
Autologous only | 4 (12.9) | 0 | 0 | 2 (33.3) | 2 (33.3) | 0 |
Allogeneic only | 3 (9.7) | 1 (16.7) | 0 | 1 (16.7) | 0 | 1 (16.7) |
Autologous and allogeneic | 6 (19.4) | 1 (16.7) | 2 (28.6) | 1 (16.7) | 2 (33.3) | 0 |
Characteristic . | All patients, N = 31, median (range) or n (%) . | Avelumab treatment group, median (range) or n (%) . | ||||
---|---|---|---|---|---|---|
70 mg Q2W, n = 6 . | 350 mg Q2W, n = 7 . | 500 mg Q2W, n = 6 . | 500 mg Q3W, n = 6 . | 10 mg/kg Q2W, n = 6 . | ||
Age, y | 38.0 (22.0-81.0) | 57.0 (31.0-78.0) | 48.0 (30.0-71.0) | 36.5 (22.0-56.0) | 35.0 (25.0-78.0) | 31.5 (25.0-81.0) |
Age group, y | ||||||
<65 | 24 (77.4) | 5 (83.3) | 4 (57.1) | 6 (100.0) | 4 (66.7) | 5 (83.3) |
≥65 | 7 (22.6) | 1 (16.7) | 3 (42.9) | 0 | 2 (33.3) | 1 (16.7) |
ECOG performance status | ||||||
0 | 14 (45.2) | 2 (33.3) | 4 (57.1) | 3 (50.0) | 3 (50.0) | 2 (33.3) |
1 | 17 (54.8) | 4 (66.7) | 3 (42.9) | 3 (50.0) | 3 (50.0) | 4 (66.7) |
Sex | ||||||
Male | 24 (77.4) | 3 (50.0) | 6 (85.7) | 5 (83.3) | 5 (83.3) | 5 (83.3) |
Female | 7 (22.6) | 3 (50.0) | 1 (14.3) | 1 (16.7) | 1 (16.7) | 1 (16.7) |
Geographic region | ||||||
North America | 10 (32.2) | 2 (33.3) | 2 (28.6) | 2 (33.3) | 2 (33.3) | 2 (33.3) |
Western Europe | 21 (67.7) | 4 (66.7) | 5 (71.4) | 4 (66.7) | 4 (66.7) | 4 (66.7) |
No. of prior anticancer therapy regimens | ||||||
1 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 2 (6.5) | 0 | 0 | 0 | 1 (16.7) | 1 (16.7) |
3 | 9 (29.0) | 2 (33.0) | 2 (28.6) | 1 (16.7) | 2 (33.3) | 2 (33.3) |
≥4 | 20 (64.5) | 4 (66.7) | 5 (71.4) | 5 (83.3) | 3 (50.0) | 3 (50.0) |
Prior treatment with brentuximab vedotin | 31 (100.0) | 6 (100.0) | 7 (100.0) | 6 (100.0) | 6 (100.0) | 6 (100.0) |
Patients with prior HSCT | 13 (41.9) | 2 (33.3) | 2 (28.6) | 4 (66.7) | 4 (66.7) | 1 (16.7) |
Type of HSCT | ||||||
Autologous only | 4 (12.9) | 0 | 0 | 2 (33.3) | 2 (33.3) | 0 |
Allogeneic only | 3 (9.7) | 1 (16.7) | 0 | 1 (16.7) | 0 | 1 (16.7) |
Autologous and allogeneic | 6 (19.4) | 1 (16.7) | 2 (28.6) | 1 (16.7) | 2 (33.3) | 0 |
ECOG, Eastern Cooperative Oncology Group; Q2W, every 2 weeks; Q3W, every 3 weeks.